{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:38Z","timestamp":1786118918791,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Focal therapy (FT) is an emerging strategy for selectively ablating prostate cancer (PCa). However, existing challenges comprise conventional techniques inadequately identifying appropriate candidates and insufficient characterization of multifocality and sampling-biases in the biopsy-based trials. We evaluated the value of adding prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptors (GRPR) PET to multiparametric MRI (PET\/mpMRI) in preoperative assessments for FT, with whole-mount pathology as a comprehensive reference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 38 men with biopsy-proven low-risk\/intermediate-risk PCa underwent mpMRI,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RM26 PET. Any focal lesion uptake (PET\n                      <jats:sub>FL<\/jats:sub>\n                      ) was considered for positive PET results, while PI-RADS for mpMRI interpretation. Index lesion was defined with the highest Gleason score or largest diameter. Detection rates for clinically significant (cs) PCa (lesion-level) and diagnostic performances for localization (segment-level) were assessed. Correct identification of FT-ineligible men (index lesion Grade Group&gt;3 or contralateral csPCa) was documented.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      For detecting the overall 73 csPCa, both\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RM26 PET\/mpMRI demonstrated significantly higher detection rates (87.7% and 94.5% vs. 72.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.005), as well as higher accuracies for localization (0.87 and 0.90 vs. 0.81,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001) than mpMRI alone. Twenty of 38 (53%) men were confirmed FT-ineligible, of which mpMRI,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA, and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RM26 PET\/mpMRI identified 12 (60%), 20 (100%) and 17 (85%), respectively. Finally,\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RM26 PET\/mpMRI identified csPCa lesions in 88.5% and 100% of FT-eligible men, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Combining PSMA\/GRPR PET and mpMRI facilitates enhanced detection rates as well as higher accuracies for localization in localized PCa.\n                      <jats:sup>68<\/jats:sup>\n                      Ga-PSMA and\n                      <jats:sup>68<\/jats:sup>\n                      Ga-RM26 PET\/mpMRI may serve as promising imaging tools to improve the preoperative assessments in FT candidates with low-risk\/intermediate-risk PCa.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005724","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:45:57Z","timestamp":1743720357000},"page":"410-418","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Using mpMRI, PSMA, and GRPR PET to Assess Focal Therapy Eligibility and Plan Treatment in Biopsy-proven Low-\/Intermediate-risk Prostate Cancer: A Whole-mount Pathology-based Study"],"prefix":"10.1097","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1633-463X","authenticated-orcid":false,"given":"Yujia","family":"Li","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Yang","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-4000","authenticated-orcid":false,"given":"Ling","family":"Xiao","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Gao","sequence":"additional","affiliation":[{"name":"Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1954-736X","authenticated-orcid":false,"given":"Axel","family":"Rominger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyu","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland"},{"name":"Department of Informatics, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5985-7701","authenticated-orcid":false,"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, Xiangya Hospital, Central South University"},{"name":"National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Tang","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"},{"name":"Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland"},{"name":"National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Hu","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine"},{"name":"National Clinical Research Center for Geriatric Disorders (XIANGYA), Xiangya Hospital, Central South University"},{"name":"Key Laboratory of Biological Nanotechnology of National Health Commission, Xiangya Hospital, Central South University, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"R1-20250403","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","article-title":"Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study","volume":"13","author":"Ahmed","year":"2012","journal-title":"Lancet Oncol"},{"key":"R2-20250403","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.juro.2007.08.072","article-title":"Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities","volume":"178","author":"Eggener","year":"2007","journal-title":"J Urol"},{"key":"R3-20250403","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"key":"R4-20250403","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","article-title":"Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience","volume":"81","author":"Reddy","year":"2022","journal-title":"Eur Urol"},{"key":"R5-20250403","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"key":"R6-20250403","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1148\/radiol.211824","article-title":"Effect of (18)F-DCFPyL PET\/CT on the management of patients with recurrent prostate cancer: results of a prospective multicenter registry trial","volume":"303","author":"Metser","year":"2022","journal-title":"Radiology"},{"key":"R7-20250403","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","article-title":"An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years?","volume":"81","author":"Hopstaken","year":"2022","journal-title":"Eur Urol"},{"key":"R8-20250403","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.08.079","article-title":"Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology","volume":"67","author":"Le","year":"2015","journal-title":"Eur Urol"},{"key":"R9-20250403","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2020.05.018","article-title":"Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus","volume":"78","author":"Lebastchi","year":"2020","journal-title":"Eur Urol"},{"key":"R10-20250403","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"R11-20250403","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"key":"R12-20250403","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1148\/radiol.2021202717","article-title":"MRI-guided focused ultrasound ablation for localized intermediate-risk prostate cancer: early results of a phase II trial","volume":"298","author":"Ghai","year":"2021","journal-title":"Radiology"},{"key":"R13-20250403","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20250403","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/S1470-2045(22)00251-0","article-title":"MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study","volume":"23","author":"Ehdaie","year":"2022","journal-title":"Lancet Oncol"},{"key":"R15-20250403","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"R16-20250403","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1097\/RLU.0000000000004819","article-title":"Impact of 18F-DCFPyL PET\/MRI in selecting men with low-\/intermediate-risk prostate cancer for focal ablative therapies","volume":"48","author":"Basso Dias","year":"2023","journal-title":"Clin Nucl Med"},{"key":"R17-20250403","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"R18-20250403","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"K\u00f6rner","year":"2014","journal-title":"Prostate"},{"key":"R19-20250403","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.117.198929","article-title":"PET using a GRPR antagonist (68)Ga-RM26 in healthy volunteers and prostate cancer patients","volume":"59","author":"Zhang","year":"2018","journal-title":"J Nucl Med"},{"key":"R20-20250403","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12894-019-0526-9","article-title":"Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry","volume":"19","author":"Bullock","year":"2019","journal-title":"BMC Urol"},{"key":"R21-20250403","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00259-023-06142-2","article-title":"A prospective comparative study of [(68)Ga]Ga-RM26 and [(68)Ga]Ga-PSMA-617 PET\/CT imaging in suspicious prostate cancer","volume":"50","author":"Gao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R22-20250403","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s00259-021-05636-1","article-title":"Dual-tracer PET\/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study","volume":"49","author":"Qiu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R23-20250403","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R24-20250403","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur Urol"},{"key":"R25-20250403","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"key":"R26-20250403","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R27-20250403","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.eururo.2013.05.048","article-title":"The role of focal therapy in the management of localised prostate cancer: a systematic review","volume":"66","author":"Valerio","year":"2014","journal-title":"Eur Urol"},{"key":"R28-20250403","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1148\/radiol.12120509","article-title":"Methods for calculating sensitivity and specificity of clustered data: a tutorial","volume":"265","author":"Genders","year":"2012","journal-title":"Radiology"},{"key":"R29-20250403","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of (68)Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"key":"R30-20250403","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2967\/jnumed.122.263889","article-title":"Comparison of (68)Ga-PSMA-617 PET\/CT and (68)Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, single-center, phase II study","volume":"64","author":"Schollhammer","year":"2023","journal-title":"J Nucl Med"},{"key":"R31-20250403","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.eururo.2020.03.048","article-title":"Negative predictive value of multiparametric magnetic resonance imaging in the detection of clinically significant prostate cancer in the prostate imaging reporting and data system era: a systematic review and meta-analysis","volume":"78","author":"Sathianathen","year":"2020","journal-title":"Eur Urol"},{"key":"R32-20250403","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bju.13306","article-title":"Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer","volume":"118","author":"Valerio","year":"2016","journal-title":"BJU Int"},{"key":"R33-20250403","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.juro.2018.06.033","article-title":"Patient reported outcome measures for transperineal template prostate mapping biopsies in the PICTURE Study","volume":"200","author":"Miah","year":"2018","journal-title":"J Urol"},{"key":"R34-20250403","doi-asserted-by":"crossref","first-page":"847","DOI":"10.2967\/jnumed.121.262398","article-title":"Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial","volume":"63","author":"Sonni","year":"2022","journal-title":"J Nucl Med"},{"key":"R35-20250403","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2967\/jnumed.122.264783","article-title":"A pilot study of (68)Ga-PSMA11 and (68)Ga-RM2 PET\/MRI for evaluation of prostate cancer response to high-intensity focused ultrasound therapy","volume":"64","author":"Duan","year":"2023","journal-title":"J Nucl Med"},{"key":"R36-20250403","article-title":"Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy","author":"Geboers","year":"2023","journal-title":"BJU Int"},{"key":"R37-20250403","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"R38-20250403","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nm.1944","article-title":"Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer","volume":"15","author":"Liu","year":"2009","journal-title":"Nat Med"},{"key":"R39-20250403","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0022-5347(01)65331-X","article-title":"Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization","volume":"157","author":"Gburek","year":"1997","journal-title":"J Urol"},{"key":"R40-20250403","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W","article-title":"Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications","volume":"180","author":"Ruijter","year":"1996","journal-title":"J Pathol"},{"key":"R41-20250403","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/MOU.0000000000000976","article-title":"Clinical and pathologic characteristics to select patients for focal therapy or partial gland ablation of nonmetastatic prostate cancer","volume":"32","author":"Jaipuria","year":"2022","journal-title":"Curr Opin Urol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:55:43Z","timestamp":1786035343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000005724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005724","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"2024-11-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}